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were incubated at 37˚C for 4 hours. A reading of each well was done 
using the MAXline Microplate Readers to evaluate pemetrexed IC50 
value. Microarray analysis was performed with Affymetrix U-133 A&B 
and plus2 chips to detect putative biomarker genes which predict peme-
trexed sensitivity. Data analysis with obtained chip data was made with 
GeneSpring software. The relative ﬂuorescent intensity by microarray 
was validated by RT-PCR on the putative gene, Synovial Sarcoma X3 
(SSX3). 
Results: Three NSCLC cell lines (H157, A549 and H1648) had over 
100 nM/L IC50 value (high IC50), and remainder NSCLC cell lines 
(H2122, H1975 and H358) had under 20 nM/L (low IC50). In Gene-
Spring analysis, 12 genes which were 5 fold higher in sensitive cell 
lines than in resistant cell lines were chosen. As SCLC cell lines are 
usually ﬂoating and difﬁcult to select resistant cell lines, 3 cell lines 
were selected as sensitive lines with low IC50 values (18-34 nM/L). 
Then 3 genes out of 12 genes were selected which were compatible in 3 
sensitive SCLC cell lines. They were Slit 2, SSX3 and EST. Sense and 
antisense primers were made for RT-PCR, and SSX3 microarray results 
were validated with those. 
Conclusion: These results need to be veriﬁed in samples from clinical 
cohorts, which are NSCLC, SCLC and malignant pleural mesothelio-
ma. It was suggested that SSX3 would predict the pemetrexed sensitiv-
ity and extend the indications of that treatment.
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Background: EGFR TKIs are effective in a small proportion of chemo-
therapy-pretreated NSCLC pts. A number of molecular alterations along 
the EGFR pathway have been proposed as predictors of response to 
EGFR TKIs, but to date none of them has been prospectively validated.
Methods: Advanced, chemotherapy-pretreated, NSCLC pts were 
screened for the following EGFR pathway alterations: EGFR gene 
mutations (by SSCP and sequencing) and/or increased copy number 
(by FISH), EGFR protein expression (by IHC), and HER-2, phosphory-
lated AKT (pAKT), and total AKT protein expression (by IHC). Upon 
progression, pts were then assigned to treatment with an EGFR TKI 
(Iressa™ or Tarceva™) according to one of the following groups: A) 
mutated (regardless of any other parameter); B) non-mutated, ampliﬁed 
(either true gene ampliﬁcation or high-grade polysomy in > 40% of 
the tumor cells); C) non-mutated, non-ampliﬁed, EGFR positive (IHC 
score ≥ 1+); D) Adk or BAC histology and no smoking history (non-
mutated, non-ampliﬁed, EGFR-negative pts or unknown EGFR status).
Results: From January 2005, 129 pts were screened for EGFR pathway 
alterations, while undergoing chemotherapy. Thirteen pts were identi-
ﬁed in group A (6 with exon 19 deletions, 6 with exon 21 point muta-
tions, 1 with both); 39 pts in group B (including 7 pts with true gene 
ampliﬁcation); 32 pts in group C (including 19 pts with a pAKT IHC 
score ≥ 1+); 7 pts in group D (including 2 pts with BAC histology). 
Treatment results in the different subgroups are reported in Table 1. 
A B C D
N. treated 11 25 25 5
PR 2 2 1 1
SD ≥ 6 mos 2 5 4 0
SD < 6 mos 2 5 4 2
PD 4 9 15 1
Too Early 1 4 1 1
Awaiting treatment 2 14 7 2
 
Conclusions: Based on the data available so far, there seems to be a 
continuum of response/ disease control rate that progressively declines 
from group A to group C. Accrual to the study will be continued in all 
4 subgroups until computer simulations using a continual reassessment 
method will allow to conﬁdently exclude a true response rate ≥ 10% in 
any of the groups.
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Background: The cytochrome P450 (CYP) is associated with tumor 
development and progression as well as activation of anti-cancer pro-
drugs and their metabolic clearance. Recently, some CYPs, in particular 
enzymes of the CYP3A subfamily (CYP3A4, CYP3A5, and CYP3A7), 
have been found to play a role in the metabolism of many anticancer 
drugs. CYP3A not only inactivates major anticancer drugs, such as 
tamoxifen, taxol and vinca alkaloids, but also activates major anti-
cancer prodrugs, such as cyclophosphamide and ifosphamide. For the 
better management of lung cancer, it is essential to understand the roles 
of CYPs and the relationships between their expression and the clinical 
feature of individual lung cancers. In this study, we investigate the ex-
pression of four CYPs (CYP1A1, CYP2A6, CYP2E1 and CYP3A) in 
78 non-small cell lung cancer (NSCLC) and their relationships to each 
other, tumor p53 expression, and clinical features of the patients. 
Materials and Methods: We examined CYPs and p53 immunoreac-
tivities in 78 Japanese patients with NSCLC who underwent surgical 
resection at UOEH after obtaining appropriate informed consent. His-
tological typing of the tumors was performed according to the WHO 
classiﬁcation (adenocarcinoma; 48 cases, squamous cell carcinoma; 
30 cases). Immunohistochemical staining (IHC) of 78 NSCLC was 
performed by the LSAB (labelled streptavidine biotin) method. CYPs 
and p53 expression was determined as positive when more than 10% 
of tumor cells were stained. The p53 mutations in 48 adenocarcinomas 
were sequenced by the dideoxy chain termination method using an ABI 
373A DNA Sequencer (Applied Biosystems). 
Results: The CYP1A1, CYP2A6, CYP2E1 and CYP3A positive rates 
in 48 adenocarcinomas were 43.8% (21/48), 45.8% (22/48), 39.6% 
